Li Kang Biomedical Co Ltd (6242) — Capital Reinvestment Ratio

Latest as of December 2025: 0.96x

Li Kang Biomedical Co Ltd (6242) has a Capital Reinvestment Ratio of 0.96x as of December 2025, meaning it reinvests 1% of its operating cash flow (NT$67.23 Million) in capital expenditures (NT$64.75 Million). See how much free cash does Li Kang Biomedical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.96x
Capex / Operating Cash Flow

Operating Cash Flow

NT$67.23 Million
TWD

Capital Expenditures

NT$64.75 Million
TWD

Data as of

Dec 2025
Most recent filing

Li Kang Biomedical Co Ltd Capital Reinvestment Ratio (2002–2025)

This chart tracks Li Kang Biomedical Co Ltd's Capital Reinvestment Ratio across 15 annual periods.

Annual Capital Reinvestment Ratio for Li Kang Biomedical Co Ltd (2002–2025)

Year-by-year Capital Reinvestment Ratio for Li Kang Biomedical Co Ltd from 2002 to 2025. For live market cap and broader valuation context, see market value of Li Kang Biomedical Co Ltd.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2025 3.58x NT$92.15 Million NT$329.54 Million ▲ +261.2%
2024 0.99x NT$65.38 Million NT$64.73 Million ▲ +2837.0%
2023 0.03x NT$96.74 Million NT$3.26 Million ▲ +96.4%
2022 0.02x NT$157.24 Million NT$2.70 Million ▼ -76.7%
2021 0.07x NT$60.45 Million NT$4.45 Million ▲ +219.7%
2020 0.02x NT$81.67 Million NT$1.88 Million ▲ +1292.6%
2019 0.00x NT$92.56 Million NT$153.00K ▼ -99.8%
2018 0.73x NT$105.53 Million NT$77.35 Million ▲ +2623.5%
2017 0.03x NT$110.61 Million NT$2.98 Million ▼ -32.8%
2016 0.04x NT$110.82 Million NT$4.44 Million ▼ -99.3%
2015 5.87x NT$63.91 Million NT$375.25 Million ▲ +3114.8%
2014 0.18x NT$41.66 Million NT$7.61 Million ▼ -16.7%
2009 0.22x NT$28.97 Million NT$6.35 Million ▼ -93.3%
2003 3.28x NT$5.63 Million NT$18.50 Million ▲ +47.1%
2002 2.23x NT$45.87 Million NT$102.38 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow